Biqiang Zheng1,2, Shuirong Zhang3, Weiluo Cai1,2, Jian Wang1,4, Ting Wang5, Ning Tang5, Yingqiang Shi1,2, Xiaoying Luo6, Wangjun Yan7,2. 1. Department of Musculoskeletal Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China. 3. OrigiMed, Shanghai, P.R. China. 4. Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China. 5. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China. 6. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China spinetumor@163.com luoxy@shsci.org. 7. Department of Musculoskeletal Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China spinetumor@163.com luoxy@shsci.org.
Abstract
BACKGROUND/AIM: Undifferentiated pleomorphic sarcoma (UPS) is an aggressive mesenchymal neoplasm characterized by chromosomal instability. The aim of this study was to identify fusion events involved in UPS. MATERIALS AND METHODS: Transcriptome sequencing was performed to search for new fusion genes in 19 UPS samples, including two paired recurrent (R) and re-recurrent (RR) samples. RESULTS: A total of 66 fusion genes were detected. Among them, 10 novel fusion genes were further confirmed by reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing. Retinoblastoma (RB1) fusions (2 cases) were the most recurrent fusion genes. The gene fusions RB1-RNASEH2B, RB1-FGF14-AS1, and E2F6-FKBP4 were correlated with the Rb/E2F pathway. Pseudogenes were involved in the formation of the gene fusions CIC-DUX4L8 and EIF2AK4-ANXA2P2. Importantly, targetable gene fusions (PDGFRA-MACROD2 and NCOR1-MAP2K1) were detected in UPS. CONCLUSION: Screening for the presence of fusion transcripts will provide vital clues to the understanding of genetic alterations and the finding of new targeted therapies for UPS. Copyright
BACKGROUND/AIM: Undifferentiated pleomorphic sarcoma (UPS) is an aggressive mesenchymal neoplasm characterized by chromosomal instability. The aim of this study was to identify fusion events involved in UPS. MATERIALS AND METHODS: Transcriptome sequencing was performed to search for new fusion genes in 19 UPS samples, including two paired recurrent (R) and re-recurrent (RR) samples. RESULTS: A total of 66 fusion genes were detected. Among them, 10 novel fusion genes were further confirmed by reverse transcription polymerase chain reaction (RT-PCR) and Sanger sequencing. Retinoblastoma (RB1) fusions (2 cases) were the most recurrent fusion genes. The gene fusions RB1-RNASEH2B, RB1-FGF14-AS1, and E2F6-FKBP4 were correlated with the Rb/E2F pathway. Pseudogenes were involved in the formation of the gene fusions CIC-DUX4L8 and EIF2AK4-ANXA2P2. Importantly, targetable gene fusions (PDGFRA-MACROD2 and NCOR1-MAP2K1) were detected in UPS. CONCLUSION: Screening for the presence of fusion transcripts will provide vital clues to the understanding of genetic alterations and the finding of new targeted therapies for UPS. Copyright
Authors: Axel Le Cesne; Sara Cresta; Robert G Maki; Jean Yves Blay; Jaap Verweij; Andrés Poveda; Paolo G Casali; Carme Balaña; Patrick Schöffski; Federica Grosso; Pilar Lardelli; Antonio Nieto; Vicente Alfaro; George D Demetri Journal: Eur J Cancer Date: 2012-06-29 Impact factor: 9.162
Authors: Robert J Canter; Shannon Beal; Dariusz Borys; Steve R Martinez; Richard J Bold; Anthony S Robbins Journal: J Am Coll Surg Date: 2009-12-04 Impact factor: 6.113
Authors: Marianna David; Nicholas C P Cross; Sonja Burgstaller; Andrew Chase; Claire Curtis; Raymond Dang; Martine Gardembas; John M Goldman; Francis Grand; George Hughes; Francoise Huguet; Louise Lavender; Grant A McArthur; Francois X Mahon; Giorgio Massimini; Junia Melo; Philippe Rousselot; Robin J Russell-Jones; John F Seymour; Graeme Smith; Alastair Stark; Katherine Waghorn; Zariana Nikolova; Jane F Apperley Journal: Blood Date: 2006-09-07 Impact factor: 22.113
Authors: Jakob Hofvander; Johnbosco Tayebwa; Jenny Nilsson; Linda Magnusson; Otte Brosjö; Olle Larsson; Fredrik Vult von Steyern; Nils Mandahl; Christopher D M Fletcher; Fredrik Mertens Journal: Clin Cancer Res Date: 2014-12-16 Impact factor: 12.531
Authors: Christopher D Steele; Maxime Tarabichi; Dahmane Oukrif; Amy P Webster; Hongtao Ye; Matthew Fittall; Patrick Lombard; Iñigo Martincorena; Patrick S Tarpey; Grace Collord; Kerstin Haase; Sandra J Strauss; Fitim Berisha; Heli Vaikkinen; Pawan Dhami; Marnix Jansen; Sam Behjati; M Fernanda Amary; Roberto Tirabosco; Andrew Feber; Peter J Campbell; Ludmil B Alexandrov; Peter Van Loo; Adrienne M Flanagan; Nischalan Pillay Journal: Cancer Cell Date: 2019-03-18 Impact factor: 31.743
Authors: Jesse R Dixon; Jie Xu; Vishnu Dileep; Ye Zhan; Fan Song; Victoria T Le; Galip Gürkan Yardımcı; Abhijit Chakraborty; Darrin V Bann; Yanli Wang; Royden Clark; Lijun Zhang; Hongbo Yang; Tingting Liu; Sriranga Iyyanki; Lin An; Christopher Pool; Takayo Sasaki; Juan Carlos Rivera-Mulia; Hakan Ozadam; Bryan R Lajoie; Rajinder Kaul; Michael Buckley; Kristen Lee; Morgan Diegel; Dubravka Pezic; Christina Ernst; Suzana Hadjur; Duncan T Odom; John A Stamatoyannopoulos; James R Broach; Ross C Hardison; Ferhat Ay; William Stafford Noble; Job Dekker; David M Gilbert; Feng Yue Journal: Nat Genet Date: 2018-09-10 Impact factor: 38.330